Comparative Pharmacology
Head-to-head clinical analysis: KANUMA versus STRENSIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANUMA versus STRENSIQ.
KANUMA vs STRENSIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Recombinant human lysosomal acid lipase (LAL) that catalyzes the hydrolysis of cholesteryl esters and triglycerides in lysosomes.
Human recombinant tissue-nonspecific alkaline phosphatase (TNSALP) that hydrolyzes inorganic pyrophosphate (PPi), a natural inhibitor of hydroxyapatite crystal growth, thereby promoting bone mineralization.
1 mg/kg intravenously over 4 hours once weekly.
6 mg/kg administered subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life: approximately 2–5 hours (range 1.5–7.5 hours) in patients with LAL deficiency. Clinical context: half-life supports weekly intravenous dosing.
Terminal elimination half-life approximately 5.1 days (123 hours) in adults; supports once-weekly subcutaneous dosing for sustained pharmacodynamic effect.
Primarily cleared via receptor-mediated endocytosis and lysosomal degradation; negligible renal or biliary/fecal elimination of active drug. <1% excreted unchanged in urine.
Renal (primarily via proteolytic catabolism into small peptides and amino acids); negligible biliary or fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy